Literature DB >> 14993501

Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy.

Francisca H Jorna1, Tom J M Tobé, Roel M Huisman, Paul E de Jong, John T M Plukker, Coen A Stegeman.   

Abstract

BACKGROUND: Secondary hyperparathyroidism can complicate renal replacement therapy (RRT) in patients with end-stage renal disease. Current medical therapies often result in hypercalcaemia and fail to correct hyperparathyroidism, but might be more effective at an early stage of disease. The aim of this study was to identify prognostic factors at the start and during the first year of RRT for refractory secondary hyperparathyroidism needing parathyroidectomy (PTx) during long-term follow-up.
METHODS: A total of 202 consecutive patients starting RRT between August 1988 and August 1996 at our centre with at least 1 year of follow-up were included. Biochemical and treatment data at the start and during the first year of RRT were collected. Univariate and multivariate analyses were used to identify risk factors for PTx during follow-up.
RESULTS: Thirty-three patients (16%) needed PTx after 52+/-23 months of RRT. Need for PTx was not different between patients undergoing haemodialysis and peritoneal dialysis, but was associated with parameters reflecting calcium and phosphate control at start and after 1 year of RRT. In a Cox multivariate model, serum parathyroid hormone [relative risk (RR): 1.02 per pmol/l; P<0.001], phosphate (RR: 1.107 per 0.1 mmol/l; P = 0.002) and alkaline phosphatase (RR: 1.004 per U/l; P = 0.049) after 1 year of RRT were independently associated with increased risk for PTx.
CONCLUSIONS: Failure of control of calcium-phosphate metabolism at the start of and early during RRT is strongly associated with PTx during long-term follow-up. Given the high prevalence of insufficient phosphate control, patients may benefit from aggressive correction of serum phosphate in the pre-dialysis and early dialysis period.

Entities:  

Mesh:

Year:  2004        PMID: 14993501     DOI: 10.1093/ndt/gfh018

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

1.  Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients.

Authors:  Yoshihiro Tominaga; Susumu Matsuoka; Nobuaki Uno; Toyonori Tsuzuki; Takahisa Hiramitsu; Norihiko Goto; Takaharu Nagasaka; Yoshihiko Watarai; Kazuharu Uchida
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

2.  Influence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney disease undergoing hemodialysis: A retrospective and prospective study.

Authors:  Lusi Setiani Agus; Imam Effendi; Syamsudin Abdillah
Journal:  Saudi Pharm J       Date:  2013-09-14       Impact factor: 4.330

Review 3.  Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis.

Authors:  Yoshihiro Tominaga; Susumu Matsuoka; Nobuaki Uno
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

4.  Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.

Authors:  Carole Nadin
Journal:  Core Evid       Date:  2005-03-31

5.  Associations between renal hyperfiltration and serum alkaline phosphatase.

Authors:  Se Won Oh; Kum Hyun Han; Sang Youb Han
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

6.  Mineral and bone disease in black african hemodialysis patients.

Authors:  Jaume Almirall
Journal:  Nephrourol Mon       Date:  2013-08-13

7.  Parathyroidectomy Associates with Reduced Mortality in Taiwanese Dialysis Patients with Hyperparathyroidism: Evidence for the Controversy of Current Guidelines.

Authors:  Li-Chun Ho; Shih-Yuan Hung; Hsi-Hao Wang; Te-Hui Kuo; Yu-Tzu Chang; Chin-Chung Tseng; Jia-Ling Wu; Chung-Yi Li; Jung-Der Wang; Yau-Sheng Tsai; Junne-Ming Sung
Journal:  Sci Rep       Date:  2016-01-13       Impact factor: 4.379

8.  Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012.

Authors:  Chung-Te Liu; Yen-Chung Lin; Yi-Chun Lin; Chih-Chin Kao; Hsi-Hsien Chen; Chih-Cheng Hsu; Mai-Szu Wu
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.